Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Moderna’s mRNA patent for COVID has been declared invalid amid its dispute with rival BioNTech. The European Patent Office reportedly nullified one of the patents involved in a lawsuit and this decision is a defeat for the Cambridge, Massachusetts-based pharmaceutical and biotech firm.
BioNTech SE revealed on Tuesday, Nov. 21, that the European Patent Office announced that the mRNA patent that Moderna was appealing to in a litigation is not valid. This was in connection to the case filed by the latter, claiming that BioNTech and Pfizer violated a patent it is using, as per Reuters.
"We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1," BioNTech said in a statement. "The European Patent Office’s decision is an important one as we believe that this and others of Moderna’s patents do not meet the requirements for grant and should never have been granted."
Moderna Loses COVID Vaccine Patent in Europe
Many manufacturers of COVID-19 vaccines have been fighting over patents. Moderna and BioNTech are two of the firms that have been engaged in heated court litigations for a long time. Pfizer, BioNTech’s partner is also involved and in the latest development, it appears that Moderna lost in its fight for mRNA’s patent in Europe after the EPO ruled it invalid.
Fierce Pharma reported that the patent owned by Moderna was canceled and this is the one that protects “respiratory virus vaccines.” Aside from Pfizer and BioNTech, France’s Sanofi S.A. is another pharmaceutical company that is opposing the patent that Moderna is trying to claim it owns the copyright to.
Patent Dispute Between Moderna and BioNTech
The dispute is mainly about two of Moderna’s patents namely: EP 3 590 949 B1 and EP 3 718 565 B1. The first one protects “ribonucleic acids containing n1-methyl-pseudouracils and uses thereof” while the second type protects “respiratory virus vaccines.”
Juve Patent mentioned that Moderna thinks Pfizer and BioNTech copied some features of these patented technologies that have become essential to the success of mRNA COVID-19 vaccines. However, on Nov. 21, the European Patent Office Opposition Division revoked one of the patents owned by Moderna, and in response, BioNTech said it welcomed the EPO’s decision.
On the other hand, Moderna said it will appeal this decision as it completely disagrees with it. The company added it believes the validity of its patent is still strong.
Photo by: Ian Hutchinson/Unsplash
